| Year | Reference |
|---|---|
|
2011
|
The preparation of human papillomavirus type 58 vaccine and exploring its biological activity and immunogenicity in vitro.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
2011 Aug;21: 988-95
|
OBJECTIVES: Human papillomavirus (HPV) type 58 is the second most prevalent virus infection among Chinese women. To develop an HPV58 vaccine that combines both prophylactic and therapeutic functions, we generate a chimeric virus-like particle (cVLP).
METHODS: The cVLPs contain both whole length L1 and parts of E7 peptides either from E7 amino acids (aa) 50 to aa72 or from E7 aa4 to aa12. The HPV58 L1-E7aa50-72 and L1-E7aa4-12 fusion proteins were revealed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and confirmed by Western blot (Supplementary Digital Content 1, http://links.lww.com/IGC/A40, which shows alignment of the protein sequence between HPV58 L1-E7aa50-72/4-12 and standard sequence). Protein folding and location of cVLPs were identified by transmission electron microscope. The immunogenicity of the fusion protein was tested by enzyme-linked immunospot assay.
RESULTS: Transmission electron microscope showed that the fusion protein formed cVLPs by self-assembly and the majority of particles located in the nucleus of the sf-9 insect cells. The cVLPs displayed a strong ability to agglutinate erythrocytes, which is distinguished from the parental VLPs. In addition, the purified HPV58 L1-E7aa50-72 or L1-E7aa4-12 fusion protein induced significant numbers of interferon γ-expressing E7aa50-72- or E7aa4-12-specific CD8 T cells.
DISCUSSION: Our results indicate that the insertion of the E7aa50-72 or E7aa4-12 peptides behind L1 did not disrupt the assembly of cVLPs and provided potent immunogenicity and bioactivity, which created a powerful basis for further preparations of HPV58 vaccines with prophylactic and therapeutic effects for the treatment of HPV58-related diseases including cervical cancer.